FDA approves Lilly's Cyramza; CEO Jimenez says more deals possible for Novartis; Merck testing human monoclonal antibody in outer space;

@FiercePharma: GlaxoSmithKline pledges $7.1B to add Novartis vaccines to its leading lineup. Story | Follow @FiercePharma

@TracyStaton: All of FiercePharma's Novartis-GSK-Lilly coverage in one place. Get it while it's hot. More | Follow @TracyStaton

@EricPFierce: FDA says import alert for saline from Baxter Canada plant tied to an importer trying to ship some to the U.S. Article | Follow @EricPFierce

@CarlyHFierce: So...who inherits Glaxo's cancer vaccine candidate? | Follow @CarlyHFierce

> The FDA has approved Eli Lilly's ($LLY) blockbuster hopeful, cancer med Cyramza. Story

> The Oklahoma Supreme Court has put a hold on the executions of two inmates it says have the right to challenge the secrecy around the drugs the state will use to put them to death. Story

> CEO Joe Jimenez says today's announced restructuring of Novartis' ($NVS) vaccine, animal health and consumer health businesses doesn't mean the Swiss drugmaker won't still be looking for some acquisitions to round out Novartis' three core operations. Story

> Taiho, the Japanese partner of Spanish pharmaceutical company Zeltia, will seek approval in Japan for their cancer drug Yondelis, which is already approved in 75 countries. Story  

> China's Shanghai Fosun Pharmaceutical Group and private equity firm TPG Capital have a deal to buy Chinese hospital operator Chindex International for about $461 million. Story

> India's Lupin has named Theresa Stevens, formerly of Astellas and Novartis ($NVS), as chief corporate development officer for its global operations. Release

Medical Device News

@FierceMedDev: Ulthera looks to $86M public offering for financial facelift. News | Follow @FierceMedDev

@VarunSaxena2: Updated with statement from Edwards: Federal court postpones Edwards' block of Medtronic's CoreValve. Story | Follow @VarunSaxena2

@EmilyWFierce: Bacterin International reports slight increase in Q1 revenues partly fueled by biologics growth. More | Follow @EmilyWFierce

@MichaelGFierce: Stanford researchers look at possible Trojan horse delivery. Story via the Stanford Daily | Follow @MichaelGFierce

> FDA deems recalled Covidien devices potentially deadly. Story

> Teleflex hit with FDA warning letter over respiratory devices. Item

Biotech News

@FierceBiotech: AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck. More | Follow @FierceBiotech

@JohnCFierce: GSK punts programs and rights on cancer to Novartis. MAGE-A3 a mess. Looks like they're done with cancer. Story | Follow @JohnCFierce

@DamianFierce: If I have past two days right: Valeant is buying Pfizer, which won an injunction against Medtronic, which is eyeing Allergan, and all are moving to Ireland. | Follow @DamianFierce

@EmilyMFierce: Experimental drug could thwart measles outbreaks. News | Follow @EmilyMFierce

> FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer. Story

> Analysts brace for a brawl as Valeant moves ahead with Allergan bid. Article

> VC groups put up $165M for a trifecta of biotech rounds. Roundup

Biotech Research News

> Researchers replicate controversial stem cell-cloning method. Story

> Experimental drug could thwart measles outbreaks. Piece

> Stabilizing protein complex in brain offers hope for Alzheimer's treatment. More

> Improved monitoring of zoonotic diseases could predict future Ebola outbreaks. Article

> Cancer stem cells responsible for treatment resistance, cancer relapse. News

> Mouse model could have predicted drug toxicity that killed 5 in clinical trial. Item

Pharma Manufacturing News

> Novartis deals with GSK and Lilly switch up manufacturing landscape. More

> FDA issued import alert after importer tried to ship saline not approved in U.S. Story

> GSK plans to unload site of closed Indian API plant. Article

> Cubist again recalls some Cubicin tied to contractor problem. Piece

> Hospira recalls 7 lots of propofol and one of lidocaine. News

> Novartis close on deal to sell contract patchmaker LTS Lohmann. Item

And Finally... Merck ($MRK) is trying to determine the physical structure of a human monoclonal antibody by crystallizing it in space aboard the SpaceX-3 cargo resupply mission launched April 14 to the International Space Station. Report

Suggested Articles

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.

Interruptions continue to wreak havoc on the global drug supply as drugmakers respond to the detection of impurities in some commonly used meds.